Structural characterization and enantioseparation of the chiral compound praziquantel

Journal of Pharmaceutical Sciences

Volumn 93, Issue 12, 2004, Pages 3039-3046

  Liu, Yue ^a   Wang, Xin ^a   Wang, Jing Kang ^b   Ching, Chi Bun ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b TIANJIN UNIVERSITY   (China)

Author keywords

Calorimetry (DSC); Chromatography; Crystallization; FTIR; X ray powder diffractometry

Indexed keywords

BETA CYCLODEXTRIN; PRAZIQUANTEL;

ARTICLE; CHIRALITY; CHROMATOGRAPHY; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DESIGN; DRUG STRUCTURE; ENANTIOMER; MELTING POINT; RACEMIC MIXTURE; STRUCTURE ANALYSIS; THERMODYNAMICS; X RAY POWDER DIFFRACTION;

EID: 10644222011     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20211     Document Type: Article

References (15)

1. Li ZJ, Grant DJW. 1997. Relationship between physical properties and crystal structures of chiral drugs. J Pharm Sci 86:1073-1078.
2. Zhang GGZ, Paspal SYL, Suryamarayanan R. 2003. Racemic species of sodium ibuprofen: Characterization and polymorphic relationships. J Pharm Sci 92:1356-1366.
3. Li ZJ, Zell MT, Munson EJ, Grant DJW. 1998. Characterization of racemic species of chiral drugs using thermal analysis, thermodynamic calculation, and structural studies. J Pharm Sci 88:337-346.
4. Wang X, Wang XJ, Ching CB. 2002. Solubility, metastable zone width, and racemic characterization of propranolol hydrochloride. Chirality 14:318-324.
5. Rodriguez-Hornedo N, Murphy D. 1999. Significance of controlling crystallization mechanisms and kinetics in pharmaceutical systems. J Pharm Sci 88:651-660.
6. Beilles S, Cardinael P, Nezie E, Petit S, Coquerel G. 2001. Preferential crystallisation and comparative crystal growth study between pure enantiomer and racemic mixture of a chiral molecule: 5-Ethyl-5-methylhydrantoin. Chem Eng Sci 56:2281-2294.
7. Tamura R, Fujimoto D, Lepp Z, Misaki K. 2002. Mechanism of preferential enrichment, an unusual enantiomeric resolution phenomenon caused by polymorphic transition during crystallization of mixed crystals composed of two enantiomers. J Am Chem Soc 124:13139-13153.
8. Pearson RC, Guerrant RL. 1983. Praziquantel: A major advance in antihelminthic therapy. Intern Med 99:194-198.
9. Lim BG, Ching CB, Tan RBH. 1995. Recovery of (-)-praziquantel from racemic mixtures by continuous chromatography and crystallization. Chem Eng Sci 50:2289-2298.
10. Lim BG, Tan RBH, Ng SC, Ching CB. 1995. Solubility phase diagram of praziquantel enantiomeric system. Chirality 7:74-81.
11. Lim BG, Ching CB. 1996. Characterization of chiral adsorbents on the chromatographic separation of praziquantel enantiomers. Ind Eng Chem Res 35(1):169-175.
12. Chen L, Zhang LF, Ching CB, Ng SC. 2002. Synthesis and chromatographic properties of a novel chiral stationary phase derived from heptakis-(6-azido-6- deoxy-2,3-di-O-phenylcarbamoylated)-β-cyclodextrin immobilized onto amino-functionalized silica gel via multiple urea linkages. J Chromatogr A 950:65-74.
13. Ng SC, Chen L, Zhang LF, Ching CB. 2002. Facile preparative HPLC enantioseparation of racemic drugs using chiral stationary phases based on mono-6-azido-6-deoxy-perphenylcarbamoylated beta-cyclodextrin immobilized on silica gel. Tetrahedron Lett 43(4):677-681.
14. Wang X, Ching CB. 2002. Liquid chromatographic retention behavior and enantiomeric separation of three chiral centre β-blocker drug (nadolol) using heptakis (6-azido-6-deoxy-2, 3-di-O-phenylcarbamolyted) β-cyclodextrin bonded chiral stationary phase. Chirality 14:798-805.
15. Jacques J, Collet A. 1991. Enantiomers, racemates, and resolutions. New York: Wiley.